A5053310047- Tissue Engineering and Regenerative Medicine
- 3D Printing in Biomedical Research
- Cardiomyopathy and Myosin Studies
- Neuroscience and Neural Engineering
- Cardiac Fibrosis and Remodeling
- Electrospun Nanofibers in Biomedical Applications
- Pluripotent Stem Cells Research
- Image and Object Detection Techniques
- Cardiovascular Effects of Exercise
- Cardiovascular Function and Risk Factors
- Pharmacological Effects and Assays
- Cardiac and Coronary Surgery Techniques
- Medication Adherence and Compliance
- Pharmaceutical Practices and Patient Outcomes
- Advanced Numerical Analysis Techniques
- Congenital heart defects research
- Endoplasmic Reticulum Stress and Disease
- Additive Manufacturing and 3D Printing Technologies
- Cardiac electrophysiology and arrhythmias
- Chemotherapy-induced cardiotoxicity and mitigation
- HER2/EGFR in Cancer Research
- Receptor Mechanisms and Signaling
- Pharmaceutical studies and practices
- Cardiac pacing and defibrillation studies
Brown University
2016-2020
John Brown University
2019
Insulin-like growth factor 1 (IGF1) and neuregulin-1 β (NRG1) play important roles during cardiac development both individually synergistically. In this study, we analyze how 3D tissue engineered from human embryonic stem cell- (hESC-) derived cardiomyocytes 2D-plated hESC-cardiomyocytes respond to developmentally relevant factors stimulate maturity characterize the therapeutic potential of IGF1 NRG1. When administered tissues, a significant decrease in active force production ~65% was...
Cardiac tissue engineering using hiPSC-derived cardiomyocytes is a promising avenue for cardiovascular regeneration, pharmaceutical drug development, cardiotoxicity evaluation, and disease modeling. Limitations to these applications still exist due in part the need more robust structural support, organization, electromechanical function of engineered cardiac tissues. It well accepted that heterotypic cellular interactions impact phenotype cardiomyocytes. The current study evaluates...
Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a valuable resource for cardiac therapeutic development; however, generation of these cells in large numbers and high purity is limitation widespread adoption. Here, design experiments (DOE) used to investigate the differentiation space three hiPSC lines when varying CHIR99027 concentration seeding density, novel image analysis developed evaluate plate coverage initiating differentiation. Metabolic selection via lactate...
Chronic stimulation of α 1A -adrenergic receptors (α -ARs) is known to mediate therapeutic effects in animal heart failure models. To investigate the chronic -AR human cardiomyocytes, we tested engineered tissue (EHT) created with iPSC-derived cardiomyocytes. RNA-seq analysis confirmed EHT expressed -ARs. (2 wk) A61603 (10 nM) increased length-dependent activation (LDA) contraction. might be beneficial for treating by restoring LDA.
Introduction: Cascade genetic screening for risk stratification is standard practice in the family of a patient diagnosed with hypertrophic cardiomyopathy (HCM), provided that pathogenic mutation present. We sought an alternative to testing cases where lacks any suspicious variants (genotype-negative). Hypothesis: Induced pluripotent stem cell (iPSC)-derived cardiomyocytes from HCM patients mutations exhibit one or more altered contractile parameters when formed into engineered heart tissues...
Introduction: Hypertrophic Cardiomyopathy (HCM) is a myocardial disease characterized by LV hypertrophy, hyperdynamic contraction, and diastolic dysfunction that results in impaired exercise capacity. In HCM, excess acto-myosin crossbridge formation during diastole increases stiffness leading to hindered ventricular filling limited cardiac reserve. EDG-7500, novel sarcomere regulator slows the rate of contraction but does not directly inhibit myosin motor head, may offer salutary effects HCM...
Introduction: Engineered heart tissues (EHTs) formed from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes carrying relevant mutations are a valuable tool for in vitro disease modeling and therapeutic testing. Tracking the emergence of phenotype is key to targeting optimal window test intervention. We hypothesized that auxotonic MyoPod® EHTs would enable longitudinal characterization with video analysis. Methods: Four scaffold designs decellularized porcine ventricular...
A lack of efficient vessel perfusion in cardiac engineered tissues affects cell viability and limits the success implanted tissues. To address need for vascular infiltration, we have developed a collagen-based construct releasing pro-angiogenic growth factors. The constructs were rodent model myocardial infarction four days after ischemia/reperfusion injury. Angiogenesis assessment was performed 4 weeks implantation by 2D histological analysis with RECA-1 antibody Microfil® (Flow Tech, MA)...
Introduction: Left-atrial dilatation is thought to play a key pathological role in facilitating remodeling both genetic and acquired cardiac myopathies, as well enabling the onset maintenance of atrial fibrillation. However, despite its likely disease, structural responses atria stretch remain understudied. The myofilament have been extensively studied ventricular tissue, where strain-dependent recruitment reserve, OFF-state, myosin heads from thick-filament contribute length dependent...
Introduction & Hypothesis: Engineered heart tissues (EHTs) formed from human induced pluripotent stem cell (hiPSC)-derived cardiomycoytes are a valuable tool for in vitro testing and new technology provides the ability to mechanically test EHTs multiple times study their longitudinal behavior. We performed these studies hypothesis that acute electrical stimulation of otherwise unpaced is sufficient improve contractile properties. Methods: were seeding hiPSC-cardiomycoytes cardiac...